Treats actinic keratosis (AK). ANDA 206493, held by Actavis Mid Atlantic. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 206493 (Diclofenac Sodium), held by Actavis Mid Atlantic, was first approved by FDA on Dec 2, 2015, with 5 approved supplements and 0 published complete response letters.
Diclofenac sodium topical gel is indicated for the topical treatment of actinic keratosis (AK).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 2, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium3% · gel;topical | Diclofenac Sodium | Rx |
| May 21, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 21, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 14, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 14, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 14, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 2, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters